CVRX
CVRx, Inc. NASDAQ Listed Jun 30, 2021$7.32
Mkt Cap $192.6M
52w Low $4.30
43.2% of range
52w High $11.30
50d MA $8.04
200d MA $8.02
P/E (TTM)
-3.9x
EV/EBITDA
-3.1x
P/B
5.3x
Debt/Equity
1.3x
ROE
-135.6%
P/FCF
-4.5x
RSI (14)
—
ATR (14)
—
Beta
1.12
50d MA
$8.04
200d MA
$8.02
Avg Volume
318.3K
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
9201 West Broadway Avenue · Minneapolis, MN 55445 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | AMC | -0.42 | -0.46 | -9.5% | 5.69 | -1.6% | -13.0% | -4.2% | +2.3% | +8.9% | +15.7% | — |
| Nov 5, 2025 | AMC | -0.50 | -0.49 | +2.0% | 9.79 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% | — |
| Aug 4, 2025 | AMC | -0.52 | -0.57 | -9.6% | 7.55 | -1.7% | -9.8% | +3.7% | -1.7% | +4.3% | +3.7% | — |
| May 8, 2025 | AMC | -0.56 | -0.53 | +5.4% | 7.78 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% | — |
| Feb 4, 2025 | AMC | -0.37 | -0.43 | -16.2% | 16.25 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% | — |
| Oct 29, 2024 | AMC | -0.45 | -0.57 | -26.7% | 10.74 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% | — |
| Jul 29, 2024 | AMC | -0.51 | -0.65 | -27.5% | 9.27 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% | — |
| Apr 30, 2024 | AMC | -0.53 | -1.04 | -96.2% | 15.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% | — |
| Jan 25, 2024 | AMC | -0.55 | -0.44 | +20.0% | 29.20 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% | — |
| Oct 26, 2023 | AMC | -0.57 | -0.43 | +24.6% | 12.84 | +15.7% | +2.4% | -1.9% | +3.7% | +1.7% | +0.1% | — |
| Jul 25, 2023 | AMC | -0.57 | -0.56 | +1.8% | 16.94 | +4.5% | +5.4% | -4.2% | +3.8% | +1.0% | +3.0% | — |
| Apr 27, 2023 | AMC | -0.57 | -0.55 | +3.5% | 9.48 | +7.5% | +22.8% | +9.5% | -1.2% | -0.5% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.81 | $7.93 | +1.5% | -1.2% | -3.1% | -1.6% | +0.0% | -1.6% |
| Feb 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $5.69 | $5.60 | -1.6% | -13.0% | -4.2% | +2.3% | +8.9% | +15.7% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $9.79 | $10.63 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% |
| Nov 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.79 | $10.63 | +8.6% | +2.7% | -3.4% | -0.4% | +1.8% | -3.3% |
| Aug 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.55 | $7.42 | -1.7% | -9.8% | +3.7% | -1.7% | +4.3% | +3.7% |
| May 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.78 | $5.97 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% |
| May 9 | JP Morgan | Downgrade | Neutral → Underweight | — | $7.78 | $5.97 | -23.3% | -38.7% | -0.4% | +14.5% | -2.8% | +17.0% |
| Apr 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.54 | $8.00 | -30.7% | -46.3% | +17.3% | -10.9% | -3.9% | +4.8% |
| Apr 8 | Lake Street | Maintains | Buy → Buy | — | $11.54 | $8.00 | -30.7% | -46.3% | +17.3% | -10.9% | -3.9% | +4.8% |
| Feb 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $16.25 | $16.07 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $16.25 | $16.07 | -1.1% | -7.2% | -2.5% | -0.5% | +1.7% | -2.1% |
| Jan 17 | Craig-Hallum | Maintains | Buy → Buy | — | $17.30 | $17.42 | +0.7% | +1.8% | +4.4% | -6.5% | +5.3% | -2.0% |
| Jan 14 | William Blair | Upgrade | Market Perform → Outperform | — | $15.04 | $16.02 | +6.5% | +7.4% | +5.3% | +1.8% | +1.8% | +4.4% |
| Dec 9 | Canaccord Genuity | Maintains | Buy → Buy | — | $13.48 | $14.17 | +5.1% | +1.2% | -0.3% | +0.1% | -1.5% | -4.3% |
| Nov 4 | Craig-Hallum | Maintains | Buy → Buy | — | $13.40 | $15.02 | +12.1% | +12.3% | +2.5% | +0.0% | +0.6% | +0.0% |
| Oct 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 30 | Lake Street | Maintains | Buy → Buy | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.74 | $10.63 | -1.0% | +31.0% | -6.8% | +2.1% | +12.3% | +2.5% |
| Oct 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $10.15 | $10.11 | -0.4% | +0.2% | -0.6% | -0.4% | +2.2% | +4.4% |
| Aug 26 | Lake Street | Maintains | Buy → Buy | — | $8.73 | $8.76 | +0.3% | +14.5% | -2.6% | +2.0% | -0.7% | +0.0% |
| Jul 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.27 | $9.03 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% |
| Jul 30 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.27 | $9.03 | -2.6% | -14.5% | +7.8% | -2.9% | -0.8% | +2.8% |
| Jul 11 | Craig-Hallum | Maintains | Buy → Buy | — | $7.15 | $7.29 | +2.0% | +19.0% | +14.2% | -0.5% | +2.5% | -2.0% |
| Jul 11 | Lake Street | Maintains | Buy → Buy | — | $7.15 | $7.29 | +2.0% | +19.0% | +14.2% | -0.5% | +2.5% | -2.0% |
| May 1 | William Blair | Downgrade | Outperform → Market Perform | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | JP Morgan | Downgrade | Overweight → Neutral | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Lake Street | Maintains | Buy → Buy | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $15.51 | $9.51 | -38.7% | -34.8% | -16.2% | +8.7% | -13.6% | +1.6% |
| Jan 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $29.20 | $29.10 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% |
| Jan 26 | JP Morgan | Maintains | Overweight → Overweight | — | $29.20 | $29.10 | -0.3% | -6.7% | -1.6% | -3.2% | -3.1% | -0.5% |
| Dec 27 | Lake Street | Maintains | Buy → Buy | — | $31.04 | $31.44 | +1.3% | -0.9% | +7.3% | -4.8% | -3.0% | -3.1% |
| Dec 20 | JP Morgan | Maintains | Overweight → Overweight | — | $23.63 | $23.51 | -0.5% | +0.9% | +6.2% | -1.3% | +24.2% | -0.9% |
| May 3 | Lake Street | Maintains | Buy → Buy | — | $12.60 | $12.88 | +2.2% | -0.5% | +0.9% | -0.3% | -2.6% | -1.9% |
| Feb 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.45 | $17.69 | +1.4% | -1.8% | +0.8% | -0.2% | +1.5% | +0.1% |
| Feb 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $18.00 | $18.51 | +2.8% | +1.9% | -9.0% | +4.5% | -1.8% | +0.8% |
| Jan 27 | JP Morgan | Maintains | Overweight → Overweight | — | $14.37 | $15.54 | +8.1% | +2.9% | -1.4% | +4.3% | +9.4% | +11.2% |
| Nov 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.24 | $11.00 | +7.4% | +1.1% | +16.3% | +1.7% | +2.6% | -5.4% |
No insider trades available.
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
CVRX's gross margin expansion to 87% signals improving operational efficiency and pricing power, while modest expense growth suggests disciplined cost management that should drive profitability gains.
Apr 13
8-K · 5.02
!!! Very High
CVRx, Inc. -- 8-K 5.02: Executive Change
CVRx granted performance stock units to executive officers to enhance retention and align incentives with near-term strategic objectives, potentially strengthening leadership stability.
Mar 3
8-K
CVRx, Inc. -- 8-K Filing
CVRx reported fourth quarter and full year 2025 financial results, with newly appointed CFO Jared Oasheim overseeing the neuromodulation medical device company's ongoing commercialization efforts.
Feb 12
Data updated apr 25, 2026 4:10am
· Source: massive.com